Non-alcoholic fatty liver disease: A patient guideline

Sven M. Francque, Giulio Marchesini, Achim Kautz, Martine Walmsley, Rebecca Dorner, Jeffrey V. Lazarus, Shira Zelber-Sagi, Kate Hallsworth, Luca Busetto, Gema Frühbeck, Dror Dicker, Euan Woodward, Marko Korenjak, José Willemse, Gerardus H. Koek, Shlomo Vinker, Mehmet Ungan, Juan M. Mendive, Christos Lionis

Research output: Contribution to journalArticlepeer-review


This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.

Original languageEnglish
Article number100322
JournalJHEP Reports
Issue number5
StatePublished - Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 The Authors

ASJC Scopus subject areas

  • Internal Medicine
  • Immunology and Allergy
  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Non-alcoholic fatty liver disease: A patient guideline'. Together they form a unique fingerprint.

Cite this